Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ventricular enlargement following infarction is a modifiable process.

M A Pfeffer1, E Braunwald

  • 1Department of Medicine, Harvard Medical School, Boston, Massachusetts.

The American Journal of Cardiology
|November 18, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modifiers of timing and possible triggers of acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Study Group.

Journal of the American College of Cardiology·1992
Same author

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

The New England journal of medicine·1992
Same author

An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point.

Circulation·1992
Same author

Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.

The New England journal of medicine·1992
Same author

Cholesterol and total mortality: need for larger trials.

BMJ (Clinical research ed.)·1992
Same author

Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study.

Journal of the American College of Cardiology·1992

Left ventricular dilation after myocardial infarction increases cardiovascular risk. Angiotensin-converting enzyme (ACE) inhibitors may reduce this dilation and improve outcomes, preserving heart structure.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Heart Failure Research

Background:

  • Left ventricular dilation and distortion post-myocardial infarction (MI) elevate the risk of adverse cardiovascular events.
  • Extensive, transmural infarcts involving the apex and persistent coronary artery occlusion predispose to ventricular enlargement.
  • Infarct expansion initiates volume enlargement, progressing to volume overload hypertrophy of remaining myocardium.

Purpose of the Study:

  • To investigate the impact of angiotensin-converting enzyme (ACE) inhibitor therapy on ventricular remodeling following acute myocardial infarction.
  • To determine if ACE inhibition preserves ventricular volume and topography post-MI.
  • To assess the effect of ACE inhibition on clinical outcomes in patients after acute myocardial infarction.

Main Methods:

Related Experiment Videos

  • Review of clinical investigations and therapeutic interventions for post-myocardial infarction ventricular remodeling.
  • Analysis of the effects of therapies aimed at limiting myocardial necrosis on ventricular architecture.
  • Evaluation of the impact of chronic ACE inhibitor administration on ventricular dilation.

Main Results:

  • Therapies limiting myocardial necrosis aid in preserving normal ventricular architecture.
  • Chronic ACE inhibitor administration has been linked to reduced ventricular dilation in the late phase of remodeling.
  • Clinical interest is high in ACE inhibition's potential to preserve ventricular volume and improve patient outcomes post-MI.

Conclusions:

  • Therapeutic interventions can modify the process of ventricular remodeling after myocardial infarction.
  • ACE inhibitors show promise in mitigating adverse ventricular remodeling and potentially improving clinical outcomes.
  • Further clinical investigation is warranted to confirm the benefits of ACE inhibition in post-MI patients.